NASDAQ Biotechnology Stock
We are a biopharmaceutical company dedicated to
discovering, developing and commercializing prescription pharmaceutical products in disease areas with significant commercial potential or unmet medical needs. Our goal is to build and commercialize a sustainable pipeline of new treatments based
upon our technical and scientific expertise, focusing in the ophthalmic and respiratory/allergy ...
more
We provide software, services and proprietary content
that enable organizations to more effectively recruit and retain employees. Our
solutions are built around a suite of easily configurable software applications
that automate talent acquisition and employee performance management best practices.
We offer the software applications that form the core of our solutions on an
on-demand basis, ...
more
— Business Risks.” Should one or more of these risks or uncertainties
materialize, or should underlying assumptions prove incorrect, actual results may vary materially
from those anticipated, believed, expected, estimated, projected, suggested or intended.
more
Abraxis BioScience, Inc., formerly known as American Pharmaceutical Partners, Inc., or APP, is an integrated global biopharmaceutical company dedicated to meeting the needs of critically ill patients.
more
The Company provides a broad range of expertise in clinical research, medical marketing, consulting
and informatics and advanced technology services to the worldwide pharmaceutical, biotechnology,
and medical device industries. The Company is managed through three business segments, namely,
Clinical Research Services (“CRS”), PAREXEL Consulting and Marketing Services ...
more
Seattle Genetics, Inc. is a biotechnology company developing monoclonal
antibody-based therapies for the treatment of cancer and autoimmune diseases. Our strategy is to advance our portfolio of product candidates in diseases with unmet medical need and significant market potential. We have an exclusive, worldwide
license agreement with Genentech to develop and commercialize our lead product ...
more
Advanced Magnetics, Inc. was incorporated in
Delaware in November 1981 and is a developer of superparamagnetic iron
oxide nanoparticles used in pharmaceutical products. We are dedicated to the
development and commercialization of our proprietary nanoparticle technology
for use in therapeutic iron compounds to treat anemia, as well as novel imaging
agents to aid in the diagnosis of ...
more
As
of
March 13, 2006, we had 26 full time employees, 4 of whom have Ph.D degrees,
3 of
whom are executive management and 13 of whom are engaged in research and
development activities. We also rely on a number of consultants. None of our
employees is represented by a collective bargaining agreement. We believe that
we have a good relationship with our ...
more
We are at an early stage
of executing our business plan, and we have a limited history of developing and
out-licensing our proprietary drug candidates and offering our drug discovery
capabilities. We have incurred significant operating and net losses and
negative cash flows from operations since our inception. As of June 30,
2006, we had an accumulated deficit of $133.7 million. We ...
more
We are an emerging specialty pharmaceutical company focused on the development of pharmaceutical products based on our proprietary drug delivery
technology platforms. We are developing pharmaceutical systems that will deliver the right drug to the right place in the right amount at the right time to treat chronic or episodic diseases and conditions. By integrating chemistry and engineering ...
more
We are a healthcare services management company focused on delivering solutions for those
suffering from alcoholism and other substance dependencies. We research, develop, license and
commercialize innovative physiological, nutritional and behavioral treatment protocols. We offer
disease management programs for substance dependence built around our proprietary ...
more
As used in this Form 10-KSB "we", "our", "us" and "SFBC" refer to SFBC International, Inc. and its subsidiaries unless the context requires otherwise. We provide pharmaceutical and biotechnology companies with specialized drug development services primarily in the areas of Phase I and Phase II clinical trials and bioanalytical laboratory services. With the acquisition of New Drug Services Inc. ...
more
· Advancing the development of our product candidates . We
currently have five product candidates in clinical development. These product
candidates, in order from the most advanced in clinical trials, are pradefovir,
CS-917, MB07803, MB07133 and MB07811 indicated for the treatment of
hepatitis B, type 2 diabetes, primary liver ...
more
Sangamo BioSciences is developing a new class of human therapeutics. We are a leader in the
research, development, and commercialization of DNA-binding proteins for the therapeutic regulation
and modification of disease-related genes. Our proprietary technology platform is based on the
engineering of a naturally occurring class of proteins referred to as zinc ...
more
Sonus Pharmaceuticals is
focused on the development of cancer drugs that are designed to provide better
efficacy, safety and tolerability, and are easier to use. Our business strategy
is as follows:
more
